Caribou Biosciences, Inc.
CRBU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $34 | $14 | $10 |
| % Growth | -71% | 148.9% | 44.3% | – |
| Cost of Goods Sold | $4 | $4 | $4 | $1 |
| Gross Profit | $6 | $31 | $10 | $9 |
| % Margin | 60.7% | 89.8% | 73.7% | 89.7% |
| R&D Expenses | $130 | $112 | $82 | $52 |
| G&A Expenses | $46 | $38 | $38 | $0 |
| SG&A Expenses | $46 | $38 | $38 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | -$4 | -$4 | $0 |
| Operating Expenses | $173 | $147 | $117 | $76 |
| Operating Income | -$167 | -$116 | -$106 | -$67 |
| % Margin | -1,667.2% | -336.6% | -768.2% | -697.8% |
| Other Income/Exp. Net | $18 | $14 | $7 | $0 |
| Pre-Tax Income | -$149 | -$102 | -$99 | -$67 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$149 | -$102 | -$99 | -$67 |
| % Margin | -1,491.9% | -296.1% | -717.8% | -697.3% |
| EPS | -1.65 | -1.38 | -1.64 | -1.11 |
| % Growth | -19.6% | 15.9% | -47.7% | – |
| EPS Diluted | -1.65 | -1.38 | -1.64 | -1.11 |
| Weighted Avg Shares Out | 90 | 74 | 61 | 60 |
| Weighted Avg Shares Out Dil | 90 | 74 | 61 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $11 | $5 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $4 | $4 | $1 |
| EBITDA | -$163 | -$113 | -$96 | -$66 |
| % Margin | -1,627.9% | -326.4% | -691% | -683.6% |